Number of employees
170
Annual revenue
$20567778
Chembio Diagnostic Systems, Inc. (OTCBB: CEMI) develops, manufactures and markets rapid tests for the detection of HIV and certain other infectious diseases. The company's current products are based upon single path lateral flow, rapid test technology platforms using proprietary and/or in-licensed technology. Chembio's patented Dual Path Platform (DPP™) is now being employed to develop several new high performance rapid test products in collaboration with others.